AXL kinase inhibitors and use of the same
Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
1. A crystalline form of a tartrate salt of the compound of structure (I):
2. The crystalline form of claim 1 , which is crystalline Form A, having a molar ratio of tartaric acid to the compound of structure (I) of about 2:1.
3. The crystalline form of claim 2 , characterized by an x-ray powder diffraction (XRPD) pattern comprising peaks, in units 2-theta, at 11.2±0.2, 17.1±0.2, and 19.9±0.2.
4. The crystalline form of claim 2 , characterized by an XRPD pattern comprising three or more peaks, in units of 2-theta, selected from 7.0±0.2, 11.2±0.2, 15.4±0.2, 16.3±0.2, 17.1±0.2, 19.9±0.2, 21.6±0.2, and 25.5±0.2.
5. A composition comprising the crystalline form of claim 2 .
6. The composition of claim 5 , comprising crystalline Form A in substantially pure form.
7. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is formulated for oral administration.
8. A unit dose comprising the pharmaceutical composition of claim 5 , wherein the unit dose comprises about 1-100 mg of the tartrate salt.
9. The crystalline form of claim 1 , wherein the tartrate salt is a salt of L-(+)-tartaric acid.
10. The crystalline form of claim 2 , wherein Form A is in substantially pure form.
11. The crystalline form of claim 4 , wherein the XRPD pattern is substantially identical to the XRPD pattern shown in FIG. 61A .